spacer
home > ebr > autumn 2017 > definitive screening designs
PUBLICATIONS
European Biopharmaceutical Review

Definitive Screening Designs

The ability to quickly develop reliable and robust analytical test methods is an important aspect of navigating the technical path to a successful investigational new drug (IND) submission. Often, an insufficient amount of time is allocated to understanding analytical methods and reference materials and how they perform at in-process test points.

Charge Heterogeneity

Analytical comprehension is particularly challenging for proteins expressed in mammalian cells, which can present extensive charge heterogeneity resulting from variations in post-translational modifications (PTMs). The milieu parameters in any given bioprocess can impact charge heterogeneity, which, when not properly understood and controlled, can cause unwanted batch-to-batch variation in product quality.

Therefore, early detection of charge heterogeneity, using a robust method with good resolution, is an important capability for process development. Some PTMs result in charge differences on the molecule that are likely to alter the protein’s stability or activity.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Srividya Suryanarayana has over five years’ industry experience at Cytovance Biologics and over seven years’ academic experience in R&D. She is a subject matter expert on charge-based analytical methods using icIEF and has a strong background in enzymology, protein biochemistry, analytical method development, qualification and validation. Srividya is a method validation lead scientist in Quality Control at Cytovance Biologics, leading method validation activities for several client-specific projects. She holds a PhD in biochemistry/biophysics from the University of Kansas, US, and has completed post-doctoral training from the Medical College of Wisconsin, US.
spacer
Dr Srividya Suryanarayana
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Clinical and Regulatory Operational Excellence Forum

1. Innovative technologies are expected to take clinical development, licensing, and other regulatory processes to the next level in the future. What do you see are the biggest challenges facing companies when trying to cope with continued data growth in a fast changing environment? Pharmaceutical companies are heavily regulated and introducing change needs proof of acceptance by the authorities. The chance that authorities do not agree with that change makes the industry risk averse. Changes in a stable GxP environment are almost by default seen as a risk, however, not adapting to new technologies should also be seen as a risk! Therefore, ICH developed the ICH Q8, Q9, Q10, Q11, and Q12 guidelines, to anticipate change and implement changes much faster, with less of a regulatory burden. Nevertheless, industry is not picking up with the desired pace. Why not?
More info >>

White Papers

Bonfiglioli Engineering Headspace Gas Analysis Systems for Parenteral Manufacturing Processes: One Step Beyond Product Quality and Patient Safety

Bonfiglioli Engineering

This white paper presents the innovative solutions that Bonfiglioli Engineering has been developing in the field of HGA and their significant advantages over other existing systems.
More info >>

 
Industry Events

PDA Parenteral Packaging 2019

19-20 March 2019, Hilton Molino Stucky, Venice, Italy

PDA Europe’s Conference has become a must-attend event for all professionals in the Parenteral Packaging arena. Join us in Venice in March 2019 to continue and further deepen scientific advancements and our ongoing professional discourse of latest on primary packaging technologies and business trends. This conference and the accompanying exhibition address quality of components and cont­ainers, container closure development and integrity testing as well as aspects of processing, product distribution and storage.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement